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Antigenic diversity has posed a critical barrier
to vaccine development against the pathogenic
blood-stage infection of the human malaria parasite
Plasmodium falciparum. To date, only strain-specific
protection has been reported by trials of such vac-
cines in nonhuman primates. We recently showed
that P. falciparum reticulocyte binding protein
homolog 5 (PfRH5), a merozoite adhesin required
for erythrocyte invasion, is highly susceptible to vac-
cine-inducible strain-transcending parasite-neutral-
izing antibody. In vivo efficacy of PfRH5-based
vaccines has not previously been evaluated. Here,
we demonstrate that PfRH5-based vaccines can pro-
tect Aotusmonkeys against a virulent vaccine-heter-
ologous P. falciparum challenge and show that such
protection can be achieved by a human-compatible
vaccine formulation. Protection was associated
with anti-PfRH5 antibody concentration and in vitro
parasite-neutralizing activity, supporting the use of
this in vitro assay to predict the in vivo efficacy of
future vaccine candidates. These data suggest that
PfRH5-based vaccines have potential to achieve
strain-transcending efficacy in humans.
INTRODUCTION
The development of a highly effective and deployable malaria
vaccine remains an urgent priority for improving global public
health. Despite recent strides in disease prevention and control,
the Plasmodium falciparum human malaria parasite continues to
exert a huge toll in terms of morbidity andmortality (Murray et al.,
2012). The most advanced malaria subunit vaccine, a virus-like
particle known as RTS,S, has shown only modest efficacy in130 Cell Host & Microbe 17, 130–139, January 14, 2015 ª2015 The Ayoung children in Phase III clinical trials (Agnandji et al., 2012),
and thus new approaches are urgently needed (Moorthy et al.,
2013).
RTS,S induces antibodies that reduce liver infection by the
parasite (Foquet et al., 2014). An alternative and complementary
strategy is to vaccinate against the subsequent blood-stage
infection (which causes clinical disease and against which natu-
ral immunity is slowly acquired). Such a vaccine could prevent
death and reduce incidence of disease, parasitemia, and onward
transmission (Hill, 2011). However, despite 25 years of develop-
ment, vaccine candidates targeting P. falciparum’s asexual
blood stage have failed to overcome the challenge posed by
the parasite’s antigenic diversity. Two of the most critical road
blocks have included exceptionally high thresholds for protec-
tive levels of antibody against known target antigens, coupled
with problematic levels of antigen polymorphism. To date, no
vaccine candidate has overcome these hurdles to achieve in vivo
protection in human clinical trials (Goodman and Draper, 2010;
Thera et al., 2011). In previous nonhuman primate (NHP) studies
(which provide the only opportunity to study the effect of vac-
cines against an uninterrupted P. falciparum blood-stage infec-
tion), blood-stage vaccine candidates have proven protective
only against vaccine-homologous parasite lines, and only
when administered with non-human-compatible adjuvants
(Dutta et al., 2009; Lyon et al., 2008).
P. falciparum reticulocyte-binding protein homolog 5 (PfRH5)
is a recently identified merozoite protein, secreted from the api-
cal organelles of the parasite during the red blood cell (RBC) in-
vasion process (Baum et al., 2009). In vitro data have identified
PfRH5 as the highest priority target in the blood-stage malaria
vaccine field for over a decade (Douglas et al., 2011). Antibodies
induced by PfRH5 vaccination of mice and rabbits overcome the
two major difficulties outlined above: (i) antibodies can block
erythrocyte invasion to high efficiency (with lower EC50 in terms
of mg/ml antigen-specific antibody than against all other known
antigens) (Douglas et al., 2014; Miura et al., 2009; Williams
et al., 2012) and (ii) most importantly, these antibodies cross-
inhibit all P. falciparum lines and field isolates tested to dateuthors
(Bustamante et al., 2013; Douglas et al., 2011; Reddy et al., 2014;
Williams et al., 2012).
The PfRH5 protein is now known to mediate a critical non-
redundant interaction with the human RBC surface protein
basigin during invasion (Crosnier et al., 2011). The PfRH5 gene
is also refractory to genetic deletion (Baum et al., 2009; Hayton
et al., 2008), unlike many other blood-stage antigens, confirming
the essential nature of its function. In the context of natural infec-
tion, PfRH5 does not appear to be a dominant target of naturally
acquired immune responses in endemic populations (Douglas
et al., 2011; Tran et al., 2014; Villasis et al., 2012), but when de-
tected, such antibody responses correlate with protective clin-
ical outcome (Tran et al., 2014), and affinity-purified anti-PfRH5
human antibodies can neutralize parasites in vitro (Patel et al.,
2013; Tran et al., 2014). The high degree of PfRH5 sequence
conservation is thus associated with low-level natural immune
pressure, but also functional constraints linked to basigin bind-
ing. Importantly, it has been shown that minimal amino acid sub-
stitutions in PfRH5 account for loss of basigin binding and/or
host RBC tropism (linked to binding basigin orthologs from other
species), suggesting the antigen may not easily escape vaccine-
induced immune pressure (Hayton et al., 2008, 2013; Wanaguru
et al., 2013). However, to date, no study has assessed the pro-
tective efficacy of PfRH5-based vaccines in vivo, and it remains
unclear whether the encouraging observations made in vitro us-
ing an assay of parasite neutralization will translate into biologi-
cally relevant antiparasitic activity. This question is of particular
importance, given the current lack of a clear correlate of vaccine
efficacy against blood-stage infection in humans (Duncan et al.,
2012) and the need to design improved strain-transcending ma-
laria vaccines that can be progressed to clinical development.
In this study, we quantitatively assessed the immunogenicity
of PfRH5-based vaccines delivered to Aotus monkeys by three
different immunization regimens, including protein-in-adjuvant
formulations (de Cassan et al., 2011) and an adenovirus/poxvirus
vectored platform previously optimized for Phase I/IIa clinical
development (Draper et al., 2008; Sheehy et al., 2012). We
also evaluated the protective efficacy of these vaccines against
a stringent vaccine-heterologous P. falciparum challenge
(Stowers and Miller, 2001). This study enabled us to monitor
the ability of PfRH5-based vaccines to both control and clear a
virulent blood-stage infection. We report that significant protec-
tion against challenge with heterologous-strain blood-stage
P. falciparum can be achieved in vivo by these vaccines,
including when using the human-compatible viral vectored
delivery platform. This protection was associated with anti-
PfRH5 antibody concentration and parasite-neutralizing activity,
supporting the use of this assay to predict the in vivo efficacy of
future vaccine candidates. These results suggest that PfRH5-
based vaccines have the potential to achieve strain-transcend-
ing efficacy in humans.
RESULTS
Evaluation of PfRH5 Vaccine Efficacy in AotusMonkeys
31 Aotus nancymaae monkeys were randomized to groups that
received protein-in-adjuvant and/or viral vectored vaccination
regimes targeting either P. falciparum RH5 or apical membrane
antigen 1 (PfAMA1), a well-studied comparator antigen thatCell Hostelicits strain-specific antibodies (Dutta et al., 2009; Remarque
et al., 2008; Thera et al., 2011) (Figure 1A). The PfRH5 protein
immunogen was pure (Figure S1A) and shown to be correctly
folded by demonstration of binding to its receptor, basigin (Cros-
nier et al., 2011) (Figure S1B). Group A received sham vaccines,
chimpanzee adenovirus serotype 63 (ChAd63) expressing
Renilla luciferase (RLuc) prime, PBS with Abisco-100 adjuvant
boost; Group B received PfRH5 protein with complete or incom-
plete Freund’s adjuvant (CFA, IFA); Group C received ChAd63
expressing PfRH5 prime, PfRH5 protein with Abisco-100 boost;
Group D received ChAd63-PfRH5 prime, modified vaccinia virus
Ankara (MVA) expressing PfRH5 boost; and Group E received
ChAd63-PfAMA1 prime, PfAMA1 protein with Abisco-100 boost.
The ChAd63-MVA vaccine delivery platform used here has now
been progressed to human clinical testing for a wide variety of
difficult disease targets, including malaria, HIV-1, and hepatitis
C virus (de Cassan and Draper, 2013; Draper and Heeney,
2010), while the use of mixed-modality adenoviral priming-pro-
tein-boost regimens has shown promise in small animals as
well as initial clinical studies (de Cassan et al., 2011; Draper
et al., 2010) (Hodgson et al., 2014). In the case of this study,
the PfRH5 vaccines encoded the 3D7 allele of the antigen, while
for PfAMA1 the ChAd63 vector expressed two alleles of the an-
tigen (3D7 and FVO), and FVO allele PfAMA1 protein was used
for the boost. The Group A sham-vaccinated animals served
as protocol-specified infectivity controls in order to confirm
consistent infection by the FVO parasite inoculum and its appro-
priate adaptation to growth in Aotus.
To evaluate the protective efficacy of the vaccines, animals
were challenged 15 days after the final vaccination by intrave-
nous administration of 104 PfRH5-vaccine-heterologous FVO
strain P. falciparum infected red blood cells (iRBC) taken from
a donor monkey. The parasitemia (Figures 1B–1F) and hemato-
crit (Hct) (Figures S1C–S1G) in the challenged animals were
monitored over time. Challenge infection with this parasite line
has proven highly virulent in Aotus nancymaae over the course
of numerous studies, requiring treatment in all control animals
administered complete Freund’s adjuvant without a blood-stage
vaccine antigen (n = 55, Table S1 and Supplemental Informa-
tion). In contrast, none of the animals immunized here with
PfRH5 protein in Freund’s adjuvant (Group B) required treat-
ment. Efficacy in this group was significant, both comparing
treatment status versus adjuvant-matched historical controls
(the protocol-specified primary analysis for this group; Kendall’s
tB = 0.703, p < 0.001 versus historical controls) and comparing
log10 cumulative parasitemia (LCP) up to the first day on which
an animal was treated (day 10) versus Group A in the current
study (p = 0.002 by Mann-Whitney test, Figure 1G). No parasites
were seen by thin-film microscopy at any point in two of the an-
imals, with only a single parasite seen on one occasion in a third
animal; the remaining three animals self-cured after periods of
microscopically patent parasitemia at levels <10,000 parasites/
ml (p/ml) (Figure 1C). To our knowledge, such robust protection
has not been observed even after vaccine-homologous chal-
lenge of Aotus immunized with P. falciparum AMA1, merozoite
surface protein 1 (PfMSP1), PfMSP3, or the erythrocyte binding
antigen 175 kDa (PfEBA175) formulated with Freund’s adjuvant
(Hisaeda et al., 2002; Jones et al., 2001; Stowers et al., 2001,






Figure 1. PfRH5 Vaccines Protect against P. falciparum Challenge
(A) Vaccination regimes. Immunizations were performed by the intramuscular route on days 0 and 54, with the exception of those containing Freund’s adjuvant,
whichwere given subcutaneously on days 0, 26, and 54. Doses usedwere 53 109 infectious units (ifu) for ChAd63 vaccines, 23 108 plaque-forming units (pfu) for
MVA, 50 mg for protein vaccines, 250 ml for Freund’s adjuvant, and 48 mg for Abisco-100.
(B–F) Time course of parasitemia for individual animals in Group A (B), Group B (C), Group C (D), Group D (E), and Group E (F). Upper horizontal dashed line
indicates the 200,000 p/ml threshold for initiation of antimalarial treatment (Rx) because of hyperparasitemia; lower horizontal dotted line indicates absence of
thin-film detectable parasites. P indicates treatment due to hyperparasitemia; A indicates treatment due to anemia; SPx30 at day 28 in Group B indicates
cessation of follow-up of three animals that had been microscopically subpatent since day 4; SC indicates self-cure in animals that had experienced sustained
parasitemia; + indicates a single animal found dead on day 16; occasional unexpected deaths have previously been recorded among Aotus both before and
during P. falciparum challenge (Darko et al., 2005; Hisaeda et al., 2002; Singh et al., 2006).
(G) Cumulative parasitemia up to day 10, the first day on which an animal was treated. *p < 0.01 versus Group A byMann-Whitney test performed with Bonferroni
correction for multiple comparison (this was the prespecified primary analysis for Groups C–E; secondary analysis for Group B).
(H) Kaplan-Meier plot of percentage untreated survival by group. Symbols are as in (B)–(F). Comparing time to treatment in each group to Group A was done by
Mann-Whitney test with Bonferroni correction for multiple comparison, p = 0.02 for each of Groups B and D.
See also Figures S1 and S5 and Table S1.
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AC D
B Figure 2. Lack of Relationship between
ELISpot and ICS Responses and Challenge
Outcome
(A–C) Relationships between challenge outcome
(LCP) and PfRH5-specific ELISpot responses (A),
IFN-g+ CD4+ T cell responses (B), and IFN-g+ CD8+
T cell responses (C) in PfRH5-vaccinated animals
(n = 17 for ELISpot, n = 16 for ICS; Groups B, C, D,
excluding the two animals for which ELISpot re-
sults were not obtained and the three animals for
which ICS results were not obtained). All panels
plot responses after subtraction of responses in
negative control unstimulated wells. Dashed line
marked ‘‘< Background’’ indicates responses of
less than the mean plus three standard deviations
(SD) of the apparent response in Group A animals.
(D) Lack of statistically significant Spearman’s rank
correlation between ELISpot and ICS-measured
immunological parameters and outcome parame-
ters (LCP or peak parasitemia; no Bonferroni
correction was made). Measurements that did
not exceed background (defined as above) were
treated as tied observations.
See also Figure S2.differed at four amino acid loci from the 3D7 clone upon which
the vaccine was based (Hayton et al., 2008). No greater level
of divergence from the 3D7 antigen was identified among 227
field parasite strains recently sequenced (Manske et al., 2012;
Williams et al., 2012).
Significant vaccine efficacy was also observed in the animals
immunized with human-compatible ChAd63-MVA PfRH5 vac-
cines (Group D), as judged using the prespecified primary
endpoint for Groups C–E of LCP up to day 10 as compared to
Group A (Figure 1G; p = 0.007 by Mann-Whitney test with Bon-
ferroni correction for multiple comparison). Similar to Freund’s
adjuvant, there are abundant pre-existing data across multiple
species to demonstrate that there is no nonspecific effect of
the viral vector vaccines used in Group D upon the rate of
Plasmodium blood-stage infection, including for P. falciparum
in malaria-challenged humans as compared to unvaccinated
infectivity controls (Ewer et al., 2013; Sheehy et al., 2012), as
well as in three rodent malaria species: P. yoelii, P. berghei, or
P. chabaudi (Biswas et al., 2012; Goodman et al., 2013). There
was also no nonspecific effect of vaccination with COPAK (a
poxvirus similar to theMVA) upon the course of P. knowlesi para-
sitemia in rhesus macaques (Weiss et al., 2007). However, as is
typical in this model, a number of animals that developed but
controlled relatively high-level parasitemia in Groups C and D
subsequently required treatment due to anemia (Figures 1H
and S1C–S1G), the severity and timing of which correlated
with the level and timing of peak parasitemia (Figures S2H–
S2J). Most importantly, unlike previous trials of a human-
compatible blood-stage vaccine delivery platform in this model,
self-cure of infection without severe anemia was observed in 4/6
animals in the ChAd63-MVA PfRH5 group and 1/7 in the
ChAd63-Protein PfRH5 group (Figures 1D, 1E, and 1H). The
four self-curing animals in the ChAd63-MVA PfRH5 group expe-
rienced median peak parasite density of 48,000 p/ml (medianCell Hostpeak percentage parasitemia 0.9%) and were afebrile and
clinically well throughout.
Immunologic Correlates of Protection
The rationale for the development of these PfRH5 vaccines was
the observation that PfRH5-specific antibodies could achieve
high levels of parasite-neutralizing in vitro growth inhibitory activ-
ity (GIA) (Bustamante et al., 2013; Douglas et al., 2011; Williams
et al., 2012). We therefore hypothesized prior to the trial that pro-
tection achieved by PfRH5 vaccines would be associated with
anti-PfRH5 antibody concentrations and in vitro GIA, but not
necessarily with cellular responses against PfRH5. To test this
hypothesis, we initially assessed humoral and cellular immune
responses by ELISA, interferon-g (IFN-g) ELISpot, and intracel-
lular cytokine staining (ICS) assays.
Antigen-specific T cell responses to a subunit vaccine have
rarely been measured in Aotus, but we were able to detect
PfRH5 and PfAMA1-specific IFN-g-producing PBMCs by
ELISpot (Figures S2A–S2C) and resolve these into CD4+ and
CD8+ T cells by ICS (Figures S2D–S2G). Therewas no correlation
between ELISpot or ICS responses and LCP or peak parasitemia
(Figures 2A–2D).
The vaccines also induced substantial PfRH5-specific anti-
body responses, as measured by ELISA with conversion into ab-
solute antigen-specific antibody concentrations achieved via
surface plasmon resonance (SPR) calibration-free concentration
analysis (CFCA) (Williams et al., 2012) (Figures 3A, S3, and S4A–
S4F). Geometric mean day-of-challenge (DoC) PfRH5-specific
antibody concentrations achieved were 700 mg/ml in Group B
(PfRH5 protein in Freund’s adjuvant), 54 mg/ml in Group C
(ChAd63-Protein PfRH5), and 320 mg/ml in Group D (ChAd63-
MVA PfRH5); the corresponding geometric mean anti-PfAMA1
(FVO allele)-specific antibody concentration in Group E was
140 mg/ml. There was a strong and statistically significant& Microbe 17, 130–139, January 14, 2015 ª2015 The Authors 133
AC D
B Figure 3. Protection Is Associated with
Prechallenge Anti-PfRH5 Antibody Con-
centration
(A) Plasma were tested by ELISA on the day of
challenge (DoC, day 69) for anti-PfRH5 (3D7) allele
(left y axis) or anti-PfAMA1 (FVO) allele (right y axis)
total IgG responses. Individual responses and
geometric mean are shown for each group. Arbi-
trary ELISA units were converted to mg/ml con-
centrations following definition of a conversion
factor by CFCA (Figure S3).
(B–D) Relationships between DoC plasma anti-
body concentration and challenge outcome. For
the 19 PfRH5-vaccinated animals, Spearman’s
rank correlation coefficient (rs) and p value are
shown for the relationship of anti-PfRH5 total IgG
concentration on DoC with the primary endpoint
(LCP) (B) and peak parasitemia (C). (D) The rela-
tionship between IVGI and antigen-specific anti-
body concentration (anti-PfRH5 in the 19 PfRH5
vaccinated animals, and anti-PfAMA1 for the 6
PfAMA1-vaccinated animals). A nonlinear regres-
sion curve was fitted to the points from the PfRH5-
vaccinated animals and used to estimate IVGI
EC50, as reported in the text. There were insuffi-
cient data for curve fitting to the PfAMA1-vacci-
nated animals.
See also Figures S3 and S4.correlation between anti-PfRH5 antibody concentration and
challenge outcome (Figures 3B–3D). These correlations were
maintained when the analysis was conducted among animals
within Groups B and D (Figures S4G and S4H). Given that these
animals serve asmatched controls for each other within a group,
such a correlation would be unlikely if protection was attributable
to a nonspecific effect of the adjuvant or the viral vaccine vector.
In vivo growth inhibition was also calculated (IVGI; the per-
centage reduction in the parasite multiplication rate (PMR) in
each animal relative to the mean in the control group, as has
been previously described; Mahdi Abdel Hamid et al., 2011).
Using nonlinear least-squares regression, the concentration of
anti-PfRH5 immunoglobulin G (IgG) required to achieve 50%
IVGI (IVGI EC50) was estimated at 185 mg/ml (95% CI 100–
330 mg/ml, using data from Groups B–D). The relationship be-
tween PfAMA1-specific antibody concentration and IVGI was
suggestive of a higher IVGI EC50 for anti-PfAMA1 IgG than for
anti-PfRH5 IgG (Figure 3D). These in vivo growth inhibition
data are thus in line with previous in vitro GIA data using purified
antigen-specific anti-PfRH5 and anti-PfAMA1 IgG from rabbits
and humans (Miura et al., 2009; Tran et al., 2014), suggesting
that parasites are quantitatively more susceptible to anti-
PfRH5 than to anti-PfAMA1 antibodies.
We subsequently assessed the functional ability of the vac-
cine-induced antibody responses to neutralize parasites in the
GIA assay. The ability of a range of concentrations of protein
G-purified total IgG to neutralize FVO (challenge-strain) parasites
was assessed (Figure 4A). There was a strong and statistically
significant relationship between GIA at 2.5 mg/ml total IgG and
IVGI, the protocol-specified primary analysis for an immunolog-
ical correlate of protection (Figure 4B). Immunological correlates
of vaccine-induced protection against other pathogens are
commonly the attainment of a particular level of in vitro activity134 Cell Host & Microbe 17, 130–139, January 14, 2015 ª2015 The Aat a certain serumdilution titer (Plotkin, 2010). Here, we observed
that the total plasma IgG concentration of animals immunized
with different regimes differed substantially (Figure 4C). We
therefore calculated a GIA50 titer, defined as the dilution factor
from the plasma IgG concentration to the IgG concentration
achieving 50% GIA. GIA50 titer was closely associated with
challenge outcome (Figure 4D), with attainment of a GIA50 titer
exceeding five appearing predictive of untreated survival.
Impact of Infection on Vaccine-Induced Responses
We alsomonitored immune responses in the period following the
challenge infection. Consistent with the poor immunogenicity of
PfRH5 in the context of natural infection (Douglas et al., 2011;
Tran et al., 2014; Villasis et al., 2012), the effect of parasite expo-
sure on PfRH5-specific antibody levels was variable (Figure 5A)
when assessing the day of challenge (day 69) versus the end of
the challenge follow-up period (day 107). In contrast, median
anti-PfAMA1 IgG levels increased across all the groups, but
most notably in Group E (Figure 5B). Nearly every animal experi-
encing a patent infection seroconverted to the 19 kDaC terminus
of PfMSP1 (PfMSP119; Figure 5C), consistent with the abundant
and immunodominant nature of this merozoite surface antigen,
supported by similar data from controlled human malaria infec-
tion (CHMI) studies in malaria-naive adult volunteers (Elias
et al., 2014). Changes in GIA measured at a constant total IgG
concentration of 2.5 mg/ml in the same period were small, with
no significant change in PfRH5-vaccinated, PfAMA1-vacci-
nated, or sham-vaccinated animals (median changes of 7%,
3%, and 6%; p = 0.21, 0.81, and 0.14, respectively, by Wil-
coxon signed-rank test). Nonetheless, GIA50 titers increased
substantially in many cases, due to increases in total plasma
IgG concentration after parasite exposure (Figures 5D and 5E).
Follow-up of animals to day 230 (161 days after challenge)uthors
AC D
B Figure 4. Attainment of 50% GIA at a Sub-
physiological IgG Concentration Predicts
Protection
(A) The in vitro GIA of purified IgG (DoC time point)
was assessed against FVO strain parasites for all
animals at a fixed concentration of 2.5 mg/ml.
Percent GIA is reported following a single cycle of
parasite growth. For animals in Groups B, C, and
D, the assays were repeated with a dilution series
of the purified IgG. The results for each individual
animal are shown.
(B) Prespecified primary analysis for an immuno-
logical correlate of protection: relationship be-
tween percent GIA using 2.5 mg/ml purified IgG in
the assay and the percent IVGI modeled from the
parasitemia data. Across all animals (n = 31),
Spearman’s rs = 0.86, p < 0.0001; among non-
control vaccinated animals only (Groups B–E, n =
25, as shown), rs = 0.92, p < 0.0001. The dashed
lines identify animals in the top right quadrant that
did not require treatment following challenge. GIA
was predictive of outcome independent of group
allocation (p = 0.004 by likelihood-ratio test
comparing a bivariate model relating IVGI with
group versus a multivariate model relating IVGI
with group plus GIA at 2.5 mg/ml).
(C) The plasma concentration of IgG in mg/ml was
assayed at the DoC time point. Individual results
and group medians are reported.
(D) GIA50 titer was calculated for Groups B, C, and D (by dividing the plasma total IgG concentration by the total IgG GIA EC50) and is plotted against peak
parasitemia. Three animals in Group C, which all required treatment, did not achieve 50%GIA at 2.5 mg/ml and were assigned tied GIA50 titers of 1. Spearman’s
rank correlation coefficient is shown.
See also Figure S5.demonstrated that, in several animals, anti-PfRH5 antibody con-
centrations were maintained at levels in excess of the IVGI EC50
for a number of months after challenge (Figure S5A).
DISCUSSION
Overall, these results demonstrate that PfRH5-based vaccines
have the potential to overcome the shortcomings of previous
blood-stage vaccines against P. falciparum (Wright and Rayner,
2014). The attainment of cross-strain protection in vivo by an an-
tigen selected on the basis of its ability to induce cross-strain GIA
in vitro strongly hints that the relationship between GIA and
protection is causal, encouraging the continued use of the assay
for candidate vaccine selection. Our findings are also consistent
with previous data linking protection with the attainment of 60%
GIA against the challenge strain at 2.5 mg/ml total IgG, suggest-
ing that the quantitative relationship between GIA and protection
may be roughly similar for different antigens (Singh et al., 2006).
Importantly, the efficacy observed here would also have been
readily detectable in a Phase IIa CHMI clinical trial (Figures
S5B and S5C). These data thus support the assertion that an effi-
cacious blood-stage vaccine candidate should be able to
demonstrate in vivo biological effects in CHMI trials prior to field
trials (Sheehy et al., 2013).
Protection in this study appeared to be mediated by pre-
formed anti-PfRH5 antibody present at the time of infection, as
distinct from a recall response against PfRH5 after challenge.
Antigen-specific antibody concentrations exceeding 100 mg/ml
have been attained in humans by other malaria vaccinesCell Hostincluding RTS,S and those targeting PfAMA1 (Kester et al.,
2009; Spring et al., 2009), but long-term maintenance of
such high-level responses may be challenging, particularly if
P. falciparum infection does not appreciably boost vaccine-
induced anti-PfRH5 responses. We have recently demonstrated
that antibodies of other specificities can act synergistically
with anti-PfRH5 antibodies in GIA assays, thus supporting an
ongoing strategy to achieve protection with substantially lower
and more easily maintained antibody concentrations (Williams
et al., 2012).
Like the functionally critical surface proteins of other chal-
lenging vaccine targets, such as HIV-1 and influenza virus, the
immunodominant antigens of Plasmodium spp. are highly vari-
able (Riley and Stewart, 2013). PfRH5 is also functionally critical,
but analogous to the pre-erythrocytic malaria antigen circum-
sporozoite protein (the basis of the RTS,S vaccine), the response
to it in the context of infection is unlikely to be of sufficient magni-
tude to be a substantial contributor to natural immunity (Douglas
et al., 2011; Murungi et al., 2013; Tran et al., 2014). Although this
immune evasion strategy is clearly successful in permitting
P. falciparum to establish repeated and chronic infections, it
has left a conserved whole-protein target that appears more
susceptible to subunit vaccination than the conserved epitopes
presented by HIV-1 and influenza.
The clinical implications of these data for PfRH5-based vac-
cines remain unknown for now and will require clinical trials to
assess immunogenicity and efficacy in humans (Figure S5D).
However, given the attainment of an unprecedented level of pro-





Figure 5. Post-Challenge Measures of Immunogenicity
(A–E) Plasma antigen-specific total IgG responses and GIA were also assessed
in thepost-challengeperiod. Individual responsesareshownand linked for each
animal in each group at the DoC time point (day 69) and at the end of the chal-
lenge monitoring period (day 107, 38 days post-challenge). Median responses
are indicated,wherepossible, byablackcross. Anti-PfRH5 (A), anti-PfAMA1 (B),
and anti-PfMSP119 (C) ELISA data are shown. (D) Plasma IgG concentration in
mg/ml. (E)GIAwasassessed as in Figure 4, initially testing all samples at 2.5mg/
ml purified IgG. If >50% GIA was observed, samples were diluted in the assay,
and theGIA50 titerwascalculated. For each animal at each timepoint,GIA50 titer
is shown on the top left y axis (where possible to calculate); otherwise, the
percent GIA at 2.5 mg/ml is indicated on the lower right y axis.
See also Figure S5.
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tractable. It is worth noting that the FVO strain of P. falciparum
has been selected for rapid growth and virulence in Aotus mon-
keys; as a result, it is considerably more virulent in these animals
(essentially universally fatal in untreated animals) than is the case
for P. falciparum in humans (in which the probability of severe
disease is thought not to exceed 15% per episode even in ma-
laria-naive infants) (Collins et al., 1994; Gupta et al., 1999). More-
over, having defined two significant correlates of protection, it
will now be possible to rationally improve PfRH5-based immuno-
gens and their delivery in order to maximize functional antipara-
sitic immunity. The optimization of PfRH5 vaccine formulations
to achieve and maintain the highest possible levels of antibody
will also be a major focus of human clinical trials that should
commence within the coming year, supported by a greater
weight of preclinical evidence than any previous blood-stage
vaccine candidate. In summary, this study provides the initial
proof of concept in NHPs that the development of a strain-tran-
scending blood-stage vaccine against P. falciparum is possible
and provides important insight into a correlate of protection
against the human malaria parasite.
EXPERIMENTAL PROCEDURES
Full experimental methods are provided in detail in the Supplemental
Information.
Vaccines
All PfRH5 vaccines were based upon the P. falciparum 3D7 clone sequence.
The production of recombinant MVA expressing full-length PfRH5 has previ-
ously been described (Douglas et al., 2011). For the current study, a ChAd63
vector expressing the same PfRH5 transgene was produced using previously
describedmethods (Goodman et al., 2010). The production of the ChAd63 and
protein PfAMA1 (FVO allele) vaccines have been reported elsewhere (Biswas
et al., 2011; Kennedy et al., 2002). The PfRH5 3D7 protein was expressed
and tested for basigin binding essentially as described (Crosnier et al., 2011).
Animals, Immunizations, Challenge, and Sample Collection
Adult female owl monkeys (Aotus nancymaae) were housed at the US Naval
Medical Research Unit No. 6 (NAMRU-6). Randomization to groups was strat-
ified by pretrial weight. All immunizations were administered under ketamine
anesthesia and performed by the intramuscular route (into the caudal quadri-
ceps), with the exception of those containing Freund’s adjuvant, which were
given subcutaneously (into the interscapular area). The study protocol was
approved by NAMRU-6’s Institutional Animal Care and Use Committee (proto-
col number NAMRU-6 11-12), the Department of the Navy Bureau of Medicine
and Surgery (NRD-748), the University of Oxford Animal Care and Ethical
Review Committee, and the Institut Nacional de Recursos Naturales (INRENA)
at the Peruvian Ministry of Agriculture.
15 days after the final vaccination, animals were challenged intravenously
with 104 FVO-strain P. falciparum iRBC taken from a donor monkey, as previ-
ously described (Stowers et al., 2001). From day 72, daily thin-film parasitemia
quantification and alternate-day Hct measurements were conducted. Animals
were treated (i) when parasite density reached R200,000/ml, (ii) when Hct
fell to %25%, (iii) upon reaching challenge day 28 (C+28) if no parasites had
been seen in the preceding week, or (iv) upon reaching C+38 (study day
107). Blood samples for immunological assays were collected from all animals’
saphenous veins under ketamine anesthesia. EDTA-anticoagulated blood was
prepared using standard methods to obtain plasma and PBMC.
Cellular Immune Assays
Ex vivo IFN-g ELISpot and ICS were performed essentially as previously
described (Draper et al., 2010). Assays used frozen PBMC and pools of
PfRH5 and PfAMA1 peptides.uthors
ELISA, CFCA, and GIA
PfAMA1 ELISAs used the same recombinant PfAMA1 FVO protein as that used
for immunization. The production of PfMSP119 protein (QKNG allele) has been
previously described (Goodman et al., 2010). Monobiotinylated PfRH5 protein
was produced for ELISAs by transient transfection of HEK293E cells (Durocher
et al., 2002). The ELISA antigen encoded the version of the PfRH5 antigen
expressed in the viral-vector vaccines (which lacks the CD4 d3+4 and His6
tags present in the protein vaccine). ELISAs were performed essentially
according to published methodology (Sheehy et al., 2011). The OD-based
ELISA results for PfAMA1 and PfRH5were converted to mg/ml using the results
of CFCA analyses, similar to that previously described (Williams et al., 2012).
Assays of GIA were performed at the PATH-MVI GIA reference laboratory,
NIAID, NIH, using purified total IgG, FVO strain P. falciparum parasites, and
a previously published method (Miura et al., 2009). A single-lifecycle assay
was performed, followed by growth quantification by colorimetric detection
of parasite lactate dehydrogenase. For each sample achieving >50% GIA at
2.5 mg/ml, total IgG GIA EC50 was calculated in terms of total IgG concentra-
tion in the well by linear interpolation. The total IgG concentration in each
plasma sample was measured using Protein A biosensors on a Fortebio Blitz
instrument (ForteBio). For each animal achieving >50% GIA at 2.5 mg/ml, the
GIA50 titer was then calculated by dividing the plasma total IgG concentration
by the total IgG GIA EC50.
Analyses and Statistics
Throughout, all reported p values are for two-tailed tests. Vaccine efficacy
endpoints were recorded, as used in a previous Aotus-P. falciparum chal-
lenge study (Lyon et al., 2008) and a study of P. knowlesi infection of rhesus
macaques (Mahdi Abdel Hamid et al., 2011). Kendall’s tau-b was used to
test a null hypothesis of equivalent outcome between Group B and historical
Freund’s control animals (see Table S1 and Supplemental Information)
using the ordinally ranked outcome data. As a secondary efficacy outcome
measure for this group (using non-adjuvant-matched control data from the
current study), LCP was compared between Groups B and A by Mann-
Whitney test. The protocol-specified primary analysis of efficacy in Groups
C, D, and E was comparison of LCP in each group to Group A by Mann-
Whitney test with Bonferroni correction for multiple comparison. A post
hoc secondary analysis of efficacy in terms of effect upon time to treatment
was performed using a Mann-Whitney test with Bonferroni correction for
multiple comparison, comparing each of Groups B, C, D, and E to Group
A. The majority of immunological parameters were nonnormally distributed,
and thus, unless detailed otherwise in the Supplemental Information,
analyses of association between immunological parameters and continuous
outcome variables were performed by Spearman’s rank correlation. The
protocol-specified primary analysis for a correlate of protection, in the
event that GIA EC50 data could not be estimated for every animal (as
was the case here for a number of the animals in Groups C and E), was
examination of the correlation between GIA at a fixed total IgG concen-
tration and IVIG.
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